Literature DB >> 24604797

An atypical case of neuroleptic malignant syndrome precipitated by valproate.

Rajesh Verma1, Vivek Junewar, Bhanu Pratap Singh Rathaur.   

Abstract

Neuroleptic malignant syndrome (NMS) can be caused by various drugs. We report a case of a 60-year-old woman who presented with high-grade fever, muscular rigidity, tachycardia, tachypnoea and altered sensorium along with seizures. She had been taking olanzapine for the past 2 years for psychosis. For the last month valproate was added to her treatment. Her blood investigations revealed hyponatraemia and raised serum ammonia and creatinine phosphokinase (CPK) levels. In view of hyperthermia, muscular rigidity, autonomic disturbances, altered mental status and raised CPK, a diagnosis of NMS was made. Valproate could have probably precipitated NMS; although the patient was taking antipsychotics for a long time, it was only with the addition of valproate that she developed these symptoms. Raised serum ammonia levels also indicated the presence of valproate toxicity. Seizures were probably due to electrolyte disturbances. Offending drugs were withdrawn. The patient improved with treatment by dopamine agonist and other supportive treatments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24604797      PMCID: PMC3948000          DOI: 10.1136/bcr-2013-202578

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Neuroleptic malignant syndrome following levomepromazine discontinuation.

Authors:  Hisashi Tanii; Keiichi Saka; Ken Inoue; Motohiro Okada
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

2.  Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.

Authors:  Brian Ladds; Pierre Thomas; Carlina Mejia; David Hauser
Journal:  Am J Psychiatry       Date:  2009-01       Impact factor: 18.112

3.  Neuroleptic Malignant syndrome (NMS): a rare presentation induced by an antiemetic - case report.

Authors:  Gursharan Lal Kashyap; Ashok G Patel
Journal:  Psychiatr Danub       Date:  2011-09       Impact factor: 1.063

Review 4.  Neuroleptic malignant syndrome secondary to quetiapine.

Authors:  Justine Schuller Gortney; Alexandria Fagan; Julie Cold Kissack
Journal:  Ann Pharmacother       Date:  2009-03-18       Impact factor: 3.154

5.  Neuroleptic malignant syndrome and atypical antipsychotic drugs.

Authors:  Jambur Ananth; Sharat Parameswaran; Sarath Gunatilake; Karl Burgoyne; Taghrid Sidhom
Journal:  J Clin Psychiatry       Date:  2004-04       Impact factor: 4.384

6.  Addition of carbamazepine to long-term treatment with neuroleptics may induce neuroleptic malignant syndrome.

Authors:  K Nisijima; Y Kusakabe; K Ohtuka; T Ishiguro
Journal:  Biol Psychiatry       Date:  1998-11-01       Impact factor: 13.382

7.  Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride.

Authors:  Petros Angelopoulos; Maria Markopoulou; Kyriakos Kyamidis; Konstantinos Bobotas
Journal:  Gen Hosp Psychiatry       Date:  2008-07-23       Impact factor: 3.238

Review 8.  Pathogenesis and treatment of neuroleptic malignant syndrome.

Authors:  M Ebadi; R F Pfeiffer; L C Murrin
Journal:  Gen Pharmacol       Date:  1990

Review 9.  Neuroleptic malignant syndrome induced by lamotrigine.

Authors:  Masamichi Ishioka; Norio Yasui-Furukori; Kojiro Hashimoto; Norio Sugawara
Journal:  Clin Neuropharmacol       Date:  2013 Jul-Aug       Impact factor: 1.592

10.  Olanzapine induced neuroleptic malignant syndrome.

Authors:  Bichitra Nanda Patra; Sudhir K Khandelwal; Mamta Sood
Journal:  Indian J Pharmacol       Date:  2013 Jan-Feb       Impact factor: 1.200

View more
  5 in total

1.  Neuroleptic Malignant Syndrome Associated with Lithium Toxicity.

Authors:  Vaibhav Patil; Rishab Gupta; Rohit Verma; Yatan Pal Singh Balhara
Journal:  Oman Med J       Date:  2016-07

Review 2.  Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis.

Authors:  Martino Belvederi Murri; Argentina Guaglianone; Michele Bugliani; Pietro Calcagno; Matteo Respino; Gianluca Serafini; Marco Innamorati; Maurizio Pompili; Mario Amore
Journal:  Drugs R D       Date:  2015-03

Review 3.  Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.

Authors:  Ramadhan Oruch; Ian F Pryme; Bernt A Engelsen; Anders Lund
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-16       Impact factor: 2.570

4.  Neuroleptic Malignant Syndrome Associated with Valproate in an Adolescent.

Authors:  Veli Yıldırım; Meltem Çobanogulları Direk; Serkan Güneş; Çetin Okuyaz; Fevziye Toros
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-02-28       Impact factor: 2.582

5.  Neuroleptic Malignant Syndrome with Adrenal Insufficiency After BNT162b2 COVID-19 Vaccination in a Man Taking Valproate: A Case Report.

Authors:  Tomohito Mizuno; Riku Takahashi; Takahiro Kamiyama; Atsushi Suzuki; Masashi Suzuki
Journal:  Am J Case Rep       Date:  2022-05-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.